Business
Bionano Genomics Announces Record Daily Attendance for 2022 Symposium with 63% Increase Relative to Last Year
Average daily attendance of 565 in 2022 versus 346 in 2021Over 4,000 registrants with attendees represented from 82 countries31 oral presentations delivered
About this update from Bionano Genomics, Inc.
[{"type":"text","content":"Average daily attendance of 565 in 2022 versus 346 in 2021Over 4,000 registrants with attendees represented from 82 countries31 oral presentations delivered across four consecutive days37 scientific posters featuring OGM in the online exhibit hallOn-demand presentations from Symposium available for remainder of 2022 SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, today announced the conclusion of Bionano’s 2022 Symposium, with record daily attendance representing a 63% increase relative to last year’s event. Bionano’s premier scientific event showcasing OGM, Symposium was held January 10-13, 2022. Symposium had over 4,000 registrants from 82 countries and featured 31 oral presentations and 37 scientific posters from genomic scientists at leading institutions, including Brigham and Women’s Hospital, MD Anderson Cancer Center, and Quest Diagnostics. During this four-day online event, presenters reported on their use of OGM and its utility for genetic disease and cancer applications. “We were impressed by the engagement at 2022 Symposium and are excited by the accomplishments of the genomic scientists from around the world who presented their data,” commented Alka Chaubey, PhD, FACMG, and Chief Medical Officer of Bionano. “Each presenter showcased how OGM can outperform legacy techniques, resolve decades-long questions in pathogenicity of genetic disease, and complement multiple sequencing-based methods. We believe the record attendance at this year’s Symposium speaks to the strong support the research community has in pushing OGM workflows forward.” Research shared over the four-day online event expanded on several applications of OGM: OGM can consolidate traditional cytogenetics techniques into a single assay for genetic disease and cancer applications. Accurate and higher resolution: Experts from multiple leading institutions demonstrated concordance of OGM with standard of care techniques and its ability to identify structural variants relevant for patient stratification and disease management.Cost-effective, scalable and fast turnaround times: Compared to standard of care workflows, OGM can provide laborat...